Rankings
▼
Calendar
ABCL Q4 2023 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena
ABCL
AbCellera Biologics Inc.
$1B
Q4 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$9M
-57.4% YoY
Gross Profit
$9M
100.0% margin
Operating Income
-$66M
-719.6% margin
Net Income
-$47M
-513.7% margin
EPS (Diluted)
$-0.16
QoQ Revenue Growth
+39.1%
Cash Flow
Operating Cash Flow
-$20M
Free Cash Flow
-$34M
Stock-Based Comp.
$16M
Balance Sheet
Total Assets
$1.5B
Total Liabilities
$336M
Stockholders' Equity
$1.2B
Cash & Equivalents
$133M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$9M
$22M
-57.4%
Gross Profit
$9M
$20M
-54.1%
Operating Income
-$66M
-$38M
-74.8%
Net Income
-$47M
-$30M
-57.7%
Revenue Segments
Research Fees
$9M
95%
Milestone Payments
$250,000
3%
License
$185,000
2%
← FY 2023
All Quarters
Q1 2024 →